Regulus Therapeutics Inc. with ticker code (RGLS) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The range between the high target price and low target price is between 1.5 and 0.5 with the average target price sitting at 1. With the stocks previous close at 1.3 this would imply there is a potential downside of -23.1%. The 50 day moving average now sits at 0.77 and the 200 day moving average is 0.69. The company has a market capitalisation of $90m. Visit the company website at: http://www.regulusrx.com
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.